https://doi.org/10.55788/52a39bf1
The findings from the randomised, prospective ALL-HEART study showed that allopurinol, a medicine commonly used to treat gout, did not reduce composite primary endpoint events, including non-fatal myocardial infarction (MI), non-fatal stroke, or cardiovascular death, in patients with ischaemic heart disease.
Preclinical and observational data have suggested that allopurinol, a xanthine oxidase inhibitor involved in oxidative stress signalling and commonly prescribed as a treatment for gout, might confer cardiovascular benefits. “The importance of serum uric acid levels, which can be reduced by allopurinol, in cardiovascular disease is controversial, and there have been different reports over the years of how important they may be,” Prof. Isla Shelagh Mackenzie (University of Dundee, UK) explained [1].
The ALL-HEART (ISRCTN32017426) study randomised 5,721 patients with ischaemic heart disease but no history of gout 1:1 to receive 600 mg of allopurinol daily or usual care. The primary endpoint was a composite of non-fatal MI, non-fatal stroke, or cardiovascular death.
Mean serum uric acid levels were reduced from 0.34 mmol/L at baseline to 0.18 mmol/L at 6 weeks of treatment, “so we can see that the treatment was effective at lowering uric acid,” Prof. Mackenzie pointed out. However, the composite primary endpoint was not met (HR 1.04; 95% CI 0.89–1.21; P=0.65), nor were there any differences between the 2 arms on any of the individual components.
“ALL-HEART is the first large, prospective, randomised trial of the effect of allopurinol on major cardiovascular outcomes in patients with ischaemic heart disease and provides robust evidence on the role of allopurinol in these patients,” concluded Prof. Mackenzie.
The invited discussant, Prof. Leslie Cho (Cleveland Clinic, OH, USA), suggested many factors could have masked any real influence of allopurinol, namely pointing to the older age of the participants (average age of 72 years) and the fact that the average length of their disease had been 10 years, suggesting chronic angina. Moreover, she felt that xanthine oxidase may not be “a major player” in the oxidative stress signalling in ischaemic heart disease, questioning whether allopurinol was the right drug to test in this setting.
- Mackenzie IS, et al. ALL-HEART – Allopurinol and cardiovascular outcomes in ischaemic heart disease. Hot Line Session 3, ESC Congress 2022, Barcelona, Spain, 26–29 August.
Copyright ©2022 Medicom Medical Publishers
Posted on
« Conservative or invasive management for high-risk kidney disease patients with ischaemia? Next Article
Medical therapy versus PCI for ischaemic cardiomyopathy »
Table of Contents: ESC 2022
Featured articles
ESC Clinical Practice Guidelines
Prevention of VT and sudden cardiac death: the new recommendations
New and first ESC cardio-oncology guideline
The 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension
Cardiovascular assessment and management of patients undergoing non-cardiac surgery
Heart Failure
Old dogs, new tricks: Acetazolamide plus loop diuretics improves decongestion
No effect of neprilysin inhibition on cognition
Dapagliflozin DELIVERs for HFmrEF/HFpEF
Meta-analysis of DELIVER and EMPEROR-Preserved
Anticoagulation
Rheumatic heart disease-associated AF: standard-of-care holds ground
New anticoagulant safe and maybe effective: PACIFIC-AMI and PACIFIC-Stroke outcomes
AXIOMATIC-SSP: Reducing risk of ischaemic stroke with factor XIa inhibition?
Evolving evidence for P2Y12 inhibition in chronic coronary syndromes: PANTHER
Prevention
Danish study suggests starting CVD screening before age 70
Polypill SECUREs win in secondary prevention in elderly
Long-term therapy with evolocumab associated with lower CV mortality
ARBs + beta-blockers may delay Marfan syndrome aortic root replacement
ENTRIGUE: Subcutaneous pegozafermin in severe hypertriglyceridaemia
Artificial Intelligence & Digital Health – What Is New
First RCT evidence for use of AI in daily practice
AI-enhanced echography supports aortic stenosis patients
Ischaemia
Medical therapy versus PCI for ischaemic cardiomyopathy
Allopurinol disappoints in ALL-HEART
Conservative or invasive management for high-risk kidney disease patients with ischaemia?
Genotype-guided antiplatelet therapy in patients receiving PCI
Other HOTLINE Sessions
BOXing out oxygen and blood pressure targets
Coronary CT angiography diagnostics compared head-to-head
High-dose influenza vaccine: mortality benefit?
FFR-guided decision-making in patients with AMI and multivessel disease
Related Articles
BOXing out oxygen and blood pressure targets
Coronary CT angiography diagnostics compared head-to-head
Take hypertension medication anyTIME
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy